Author:
Lin Jiecong,Nguyen My Anh,Lin Linda Y.,Zeng Jing,Verma Archana,Neri Nola R.,da Silva Lucas Ferreira,Mucci Adele,Wolfe Scot,Shaw Kit L,Clement Kendell,Brendel Christian,Pinello Luca,Pellin Danilo,Bauer Daniel E.
Abstract
ABSTRACTGenome editing with RNA-guided DNA binding factors carries risk of off-target editing at homologous sequences. Genetic variants may introduce sequence changes that increase homology to a genome editing target, thereby increasing risk of off-target editing. Conventional methods to verify candidate off-targets rely on access to cells with genomic DNA carrying these sequences. However, for candidate off-targets associated with genetic variants, appropriate cells for experimental verification may not be available. Here we develop a method, Assessment By Stand-in Off-target LentiViral Ensemble with sequencing (ABSOLVE-seq), to integrate a set of candidate off-target sequences along with unique molecular identifiers (UMIs) in genomes of primary cells followed by clinically relevant gene editor delivery. Gene editing of dozens of candidate off-target sequences may be evaluated in a single experiment with high sensitivity, precision, and power. We provide an open-source pipeline to analyze sequencing data. This approach enables experimental assessment of the influence of human genetic diversity on specificity evaluation during gene editing therapy development.
Publisher
Cold Spring Harbor Laboratory